Zacks Investment Research cut shares of Chiasma (NASDAQ:CHMA) from a buy rating to a hold rating in a research report sent to investors on Thursday morning, Zacks.com reports.

According to Zacks, “Chiasma, Inc. is a biopharmaceutical company. The company’s TPE(R) technology develops oral peptides and other molecules. Its primary product candidate consists of oral octreotide which is in different clinical trial. Chiasma, Inc. is based in Newton, USA. “

CHMA has been the subject of a number of other research reports. HC Wainwright restated a buy rating and set a $11.00 price objective on shares of Chiasma in a report on Tuesday, July 23rd. Cantor Fitzgerald set a $18.00 target price on Chiasma and gave the company a buy rating in a research report on Friday, June 28th. ValuEngine lowered Chiasma from a buy rating to a hold rating in a research report on Thursday, August 1st. Brookline Capital Management reaffirmed a buy rating on shares of Chiasma in a research report on Wednesday, July 24th. Finally, Piper Jaffray Companies initiated coverage on Chiasma in a research report on Wednesday, July 31st. They set an overweight rating and a $11.00 target price on the stock. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Chiasma currently has a consensus rating of Buy and a consensus target price of $12.35.

CHMA traded down $0.16 during trading hours on Thursday, reaching $5.08. 8,740 shares of the company’s stock traded hands, compared to its average volume of 395,653. The firm has a 50-day moving average price of $5.22 and a 200 day moving average price of $6.07. Chiasma has a 52-week low of $2.11 and a 52-week high of $9.25. The firm has a market capitalization of $221.55 million, a PE ratio of -3.96 and a beta of 1.19.

Chiasma (NASDAQ:CHMA) last posted its quarterly earnings data on Thursday, August 8th. The biotechnology company reported ($0.25) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.29) by $0.04. Sell-side analysts forecast that Chiasma will post -1.09 EPS for the current fiscal year.

In other news, Director Scott Minick bought 9,818 shares of the business’s stock in a transaction dated Tuesday, August 20th. The shares were acquired at an average price of $5.19 per share, for a total transaction of $50,955.42. Following the completion of the transaction, the director now owns 62,531 shares of the company’s stock, valued at $324,535.89. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Roni Mamluk sold 10,000 shares of the business’s stock in a transaction dated Tuesday, July 16th. The shares were sold at an average price of $6.35, for a total value of $63,500.00. Following the completion of the transaction, the director now owns 10,000 shares in the company, valued at approximately $63,500. The disclosure for this sale can be found here. 8.30% of the stock is currently owned by company insiders.

Several institutional investors have recently modified their holdings of the stock. Cubist Systematic Strategies LLC raised its holdings in Chiasma by 35.4% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 14,235 shares of the biotechnology company’s stock valued at $106,000 after acquiring an additional 3,722 shares during the last quarter. Millennium Management LLC purchased a new position in Chiasma in the 4th quarter valued at about $41,000. Quantitative Systematic Strategies LLC purchased a new position in Chiasma in the 2nd quarter valued at about $100,000. Deutsche Bank AG boosted its position in Chiasma by 27.8% in the 4th quarter. Deutsche Bank AG now owns 78,198 shares of the biotechnology company’s stock valued at $243,000 after buying an additional 16,996 shares during the last quarter. Finally, Citadel Advisors LLC bought a new position in shares of Chiasma during the second quarter worth about $145,000. Hedge funds and other institutional investors own 53.19% of the company’s stock.

About Chiasma

Chiasma, Inc, a clinical-stage biopharmaceutical company, focuses on developing oral medications using transient permeability enhancer technology platform for the treatment of rare and serious chronic disease in the United States, Europe, and internationally. The company offers oral octreotide capsules for adult patients under the MYCAPSSA name, which is in two Phase III clinical trials for the treatment of acromegaly, a condition that results in the body's production of excess growth hormone.

Featured Article: Accumulation/Distribution

Get a free copy of the Zacks research report on Chiasma (CHMA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Chiasma (NASDAQ:CHMA)

Receive News & Ratings for Chiasma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chiasma and related companies with MarketBeat.com's FREE daily email newsletter.